NCT05510622 Uterine Microbiome in Recurrent Pregnancy Loss
| NCT ID | NCT05510622 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mỹ Đức Hospital |
| Condition | Recurrent Pregnancy Loss, Not Pregnant |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-12-12 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2022-12-12 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The female genital tract microbiome may reflect female reproductive health and may be related to pregnancy outcomes. Disturbances in this microbiome may be associated with adverse reproductive outcomes. The investigators hypothesize that the endometrial and vaginal microbiome composition in women with a history of recurrent pregnancy loss are different, compared with those in normal fertile women.
Eligibility Criteria
1. Recurrent pregnancy loss patients Inclusion Criteria: * 18-38 years old * Having a regular menstrual cycle, from 25 to 35 days * Having ≥ 2 recurrent pregnancy loss and * Couples with normal karyotype results * Having no condition causing pregnancy loss such as antiphospholipid syndrome, abnormal thyroid function. * Agree to participate in the study Exclusion Criteria: * Irregular menstrual cycle * Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal fibroid) * Using intrauterine device within the last 3 months * Using antibiotic/vaginal pessary/contraceptive pills within 2 weeks * Having sexual intercourse within 48 hours 2. Healthy control patients Inclusion Criteria: * 18-38 years old * Having a regular menstrual cycle, from 25 to 35 days * No history of pregnancy loss * Having 1 or more live birth, with the youngest child ≥ 6 months old * Agree to participate in the study Exclusion Criteria: * Irregular menstrual cycle * Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal fibroid) * Using intrauterine device within the last 3 months * Using antibiotic/vaginal pessary/contraceptive pills within 2 weeks * Having sexual intercourse within 48 hours
Contact & Investigator
Lan N Vuong, MD, PhD
STUDY CHAIR
University of Medicine and Pharmacy at Ho Chi Minh City
Frequently Asked Questions
Who can join the NCT05510622 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 38 Years, studying Recurrent Pregnancy Loss, Not Pregnant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05510622 currently recruiting?
Yes, NCT05510622 is actively recruiting participants. Contact the research team at bsnam.nt@myduchospital.vn for enrollment information.
Where is the NCT05510622 trial being conducted?
This trial is being conducted at Ho Chi Minh City, Vietnam, Ho Chi Minh City, Vietnam.
Who is sponsoring the NCT05510622 clinical trial?
NCT05510622 is sponsored by Mỹ Đức Hospital. The principal investigator is Lan N Vuong, MD, PhD at University of Medicine and Pharmacy at Ho Chi Minh City. The trial plans to enroll 100 participants.